[go: up one dir, main page]

MA62912A1 - Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1) - Google Patents

Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1)

Info

Publication number
MA62912A1
MA62912A1 MA62912A MA62912A MA62912A1 MA 62912 A1 MA62912 A1 MA 62912A1 MA 62912 A MA62912 A MA 62912A MA 62912 A MA62912 A MA 62912A MA 62912 A1 MA62912 A1 MA 62912A1
Authority
MA
Morocco
Prior art keywords
usp1
ubiquitin
inhibition
specific protease
compounds
Prior art date
Application number
MA62912A
Other languages
English (en)
Inventor
Alexandre Joseph Buckmelter
Loren Berry
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MA62912A1 publication Critical patent/MA62912A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente divulgation concerne des composés permettant d'inhiber usp1, et des procédés associés de préparation et d'utilisation des composés.
MA62912A 2021-04-07 2022-04-06 Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1) MA62912A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163171796P 2021-04-07 2021-04-07
PCT/US2022/023669 WO2022216820A1 (fr) 2021-04-07 2022-04-06 Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1)

Publications (1)

Publication Number Publication Date
MA62912A1 true MA62912A1 (fr) 2024-05-31

Family

ID=83546542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA62912A MA62912A1 (fr) 2021-04-07 2022-04-06 Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1)

Country Status (14)

Country Link
US (1) US20240239808A1 (fr)
EP (1) EP4319758A4 (fr)
JP (1) JP2024514322A (fr)
KR (1) KR20230167071A (fr)
CN (1) CN117241801A (fr)
AU (1) AU2022254062A1 (fr)
BR (1) BR112023019075A2 (fr)
CA (1) CA3214040A1 (fr)
CL (1) CL2023002956A1 (fr)
IL (1) IL307157A (fr)
MA (1) MA62912A1 (fr)
MX (1) MX2023011709A (fr)
TN (1) TN2023000250A1 (fr)
WO (1) WO2022216820A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CN117136189A (zh) * 2021-04-09 2023-11-28 先声再明医药有限公司 泛素特异性蛋白酶1（usp1）抑制剂
PE20241234A1 (es) * 2021-11-12 2024-06-19 Insilico Medicine Ip Ltd Inhibidores de molecula pequena de proteasa especifica de ubiquitina 1 (usp1) y usos de los mismos
KR20240117556A (ko) 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
CA3235603A1 (fr) * 2021-11-12 2023-05-19 Insilico Medicine Ip Limited Inhibiteurs a petites molecules de la protease 1 specifique de l'ubiquitine (usp1) et leurs utilisations
WO2023143424A1 (fr) * 2022-01-27 2023-08-03 四川海思科制药有限公司 Dérivé azacyclique et son application médicale
WO2023148643A1 (fr) * 2022-02-03 2023-08-10 Aurigene Oncology Limited Composés hétérocyclyles bicycliques fusionnés utilisés en tant qu'inhibiteurs d'usp1
CA3250418A1 (fr) * 2022-04-29 2025-07-08 Asieris Pharmaceuticals (Shanghai) Co., Ltd. Composé de pyrimidine, son procédé de préparation et son utilisation pharmaceutique
CN117003757A (zh) * 2022-05-07 2023-11-07 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
EP4547336A1 (fr) * 2022-06-29 2025-05-07 Zentaur Therapeutics USA Inc. Inhibiteurs de usp1 et utilisations associées
WO2024022266A1 (fr) * 2022-07-25 2024-02-01 Guangdong Newopp Biopharmaceuticals Co., Ltd. Composés hétéroaryle utilisés comme inhibiteurs de usp1
CN119522224A (zh) * 2022-08-09 2025-02-25 上海济煜医药科技有限公司 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
TW202411231A (zh) * 2022-09-09 2024-03-16 大陸商正大天晴藥業集團股份有限公司 用作泛素-特異性蛋白酶抑制劑的取代嘌呤酮衍生物
AU2023343945A1 (en) * 2022-09-20 2025-04-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Carbonyl fused heterocyclic derivative used as ubiquitin-specific protease inhibitor
CN120092007A (zh) * 2022-10-09 2025-06-03 海南先声再明医药股份有限公司 杂环并嘧啶类化合物、药物组合物及其应用
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2024153175A1 (fr) * 2023-01-19 2024-07-25 Laekna Therapeutics Shanghai Co., Ltd. Composés hétéroaromatiques et leur utilisation en tant qu'inhibiteurs de usp1
WO2025007777A1 (fr) * 2023-07-05 2025-01-09 江苏亚虹医药科技股份有限公司 Composé de pyrimidine, son procédé de préparation et son utilisation médicale
WO2025010245A1 (fr) 2023-07-06 2025-01-09 Exelixis, Inc. Dérivés de pyrazole fusionnés en tant qu'inhibiteurs d'usp1
WO2025067259A1 (fr) * 2023-09-26 2025-04-03 上海济煜医药科技有限公司 Procédé de préparation d'un composé amine hétérocyclique azoté qui agit en tant qu'inhibiteur de protéase 1 spécifique de l'ubiquitine, et application et utilisation
US20250145590A1 (en) * 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (fr) * 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Composés relatifs à la protéase 1 spécifique de l'ubiquitine (usp1)
WO2025096505A1 (fr) * 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Composés de type protéase 1 spécifique de l'ubiquitine (usp1)
WO2025096487A1 (fr) * 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Composés de type protéase 1 spécifique de l'ubiquitine (usp1)
WO2025102016A1 (fr) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Nouvelles molécules utilisées en tant qu'inhibiteurs de la voie de réparation des dommages à l'adn
TW202539659A (zh) 2024-01-10 2025-10-16 美商維瑞斯治療股份有限公司 Ｄｎａ損傷修復途徑的新穎抑制劑
TW202535379A (zh) * 2024-01-26 2025-09-16 大陸商成都微芯藥業有限公司 Ｕｓｐ１抑制劑及其製備方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9518032B2 (en) * 2010-04-30 2016-12-13 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of USP1 deubiquitinating enzyme activity
US9802904B2 (en) * 2012-12-28 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
AU2016356694B2 (en) * 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
JP7662519B2 (ja) * 2018-12-20 2025-04-15 ケーエスキュー セラピューティクス， インコーポレイテッド 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用
CN113474346B (zh) * 2018-12-28 2024-12-27 福马治疗有限公司 用于抑制泛素特异性蛋白酶1的组合物

Also Published As

Publication number Publication date
EP4319758A1 (fr) 2024-02-14
MX2023011709A (es) 2023-10-12
IL307157A (en) 2023-11-01
AU2022254062A1 (en) 2023-10-12
WO2022216820A1 (fr) 2022-10-13
EP4319758A4 (fr) 2025-07-30
JP2024514322A (ja) 2024-04-01
KR20230167071A (ko) 2023-12-07
CL2023002956A1 (es) 2024-03-08
CA3214040A1 (fr) 2022-10-13
TN2023000250A1 (en) 2025-07-02
CN117241801A (zh) 2023-12-15
US20240239808A1 (en) 2024-07-18
BR112023019075A2 (pt) 2023-10-17

Similar Documents

Publication Publication Date Title
MA62912A1 (fr) Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1)
NZ506329A (en) Inhibitors of phospholipase enzymes
PH12021552862A1 (en) Fgfr inhibitors and methods of use thereof
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
ES2173341T3 (es) Compuestos inhibidores de proteasa retroviral.
FI971489A0 (fi) Uusia bentsoksatsoleja
MXPA04003169A (es) Profarmacos de compuestos policiclicos sustituidos utiles para inhibicion selectiva de la cascada de coagulacion.
AP9200410A0 (en) Retroviral protease inhibitors.
DE69816280D1 (de) Inhibitoren des impdh-enzyms
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
MX2024013215A (es) Compuestos para inhibir kif18a
TNSN05105A1 (en) Novel bicyclic inhibitors of hormone sensitive lipase
ATE363276T1 (de) Tripeptidylpeptidase-hemmer
PT941221E (pt) Dihidrobenzofuranos substituidos como inibidores de fosfodiesterase (pde)
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
ATE443044T1 (de) Tace inhibitoren
MY141020A (en) Novel pparalpha and ppargamma agonists
FR3097557B1 (fr) Nouvel agent de biocontrole et son utilisation pour la lutte contre des maladies fongiques de plantes
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
MX2023004115A (es) Compuestos del inhibidor de la autotaxina.
SE9604582D0 (sv) Novel compounds
UA80869C2 (en) Phosphonic acid compounds as serine proteinase inhibitors
UA26982A1 (uk) Похідhі малоhової кислоти, які проявляють властивості іhгібітору росту рослиh
DK1261325T3 (da) Tumorinhiberende sammensætninger, der indeholder nitroacridiner
WO2003104479A3 (fr) Identification d'inhibiteurs de la mitose